ACIU
AC Immune SA
NASDAQ · Healthcare · Biotechnology · CH
$2.20
+5.26%Nov 4, 2026, 14:56 UTC
AC Immune SA reported a quarterly loss of $0.16 per share, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.22 loss and a $0.20 loss per share a year earlier.
Source:Aug 5, 2026, 11:00 UTC
AC Immune initiated the Alzheimer's disease AD4 cohort in the ABATE trial, triggering a $12 million milestone payment from Takeda.
Source:Aug 5, 2026, 11:00 UTC
AC Immune reported financial results for the half-year ended June 30, 2026, with cash resources of CHF 75.4 million.
Source: